1-15 of 15
Madeleine Etienne, CRA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Franck E. Nicolini, MD PhD, Gabriel Etienne, MD PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, MD, Laurence Legros, MD, Stéphane Giraudier, MD PhD, Valérie Coiteux, MD, Agnes Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, Shanti Amé, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD PhD, Marie-Claude Gagnieu, PharmD, PhD, Stéphane Morisset, Stat, Christine Pivot, PharmD, Madeleine Etienne, CRA, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1578.
https://doi.org/10.1182/blood.V126.23.1578.1578
Published: 2015
Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2774.
https://doi.org/10.1182/blood.V126.23.2774.2774
Published: 2015
Journal Articles

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Gaelle Fossard, MD, Emilie Blond, Pharm.D, Stephane Giraudier, MD PhD, Stephane Morisset, Stat., Jeremy Ruby, CRA student, Martine Escoffre-Barbe, MD, Hélène Labussière-Wallet, MD, Mael Heiblig, MD, Madeleine Etienne, CRA, Jocelyne Drai, Pharm.D, Mohamad Sobh, Pharm.M., Mauricette Michallet, MD PhD, Isabelle Redonnet-vernhet, MD PhD, Jean-christophe Lega, MD PhD, Gabriel Etienne, MD PhD, Franck E. Nicolini, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3136.
https://doi.org/10.1182/blood.V124.21.3136.3136
Published: 2014
Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD
Journal: Blood
Blood (2013) 122 (21): 2721.
https://doi.org/10.1182/blood.V122.21.2721.2721
Published: 2013
Journal Articles

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Franck E. Nicolini, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Mael Heiblig, MD, Emilie Blond, Pharm.D, Laurence Legros, MD, PhD, Yann Guillermin, MD, Stephane Morisset, Stat., Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Jeremy Ruby, CRA student, Mohamad Sobh, Pharm.M., Gaelle Richard-Colmant, MD, Celine Fettig, Tech., Mauricette Michallet, MD, PhD, Delphine Rea, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4020.
https://doi.org/10.1182/blood.V122.21.4020.4020
Published: 2013
Journal Articles

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

Franck E. Nicolini, MD, PhD, Françoise Huguet, Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Marie-Pierre Fort, CRA, Isabelle Tigaud, MD, Sandrine Hayette, Stephane Morisset, Stat., Mohamad Sobh, Pharm.M., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Myriam Daudin, MD, Volcy Soula, MD, Sandrine Giscard d'Estaing, MD, Gabriel Etienne, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1669.
https://doi.org/10.1182/blood.V120.21.1669.1669
Published: 2012
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free Survival

Mauricette Michallet, MD, PhD, Hélène Labussière-Wallet, MD, Mohamad Sobh, Pharm.M., Stéphane Morisset, Stat., Madeleine Etienne, CRA, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Xavier Thomas, MD, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, Franck E. Nicolini, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4437.
https://doi.org/10.1182/blood.V120.21.4437.4437
Published: 2012
Journal Articles

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Anne-Claire Barale, Caroline Serrier, MD, Isabelle Tigaud, MD, Sandrine Hayette, Oriane Le Borgne, CRA, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3756.
https://doi.org/10.1182/blood.V120.21.3756.3756
Published: 2012
Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1684.
https://doi.org/10.1182/blood.V118.21.1684.1684
Published: 2011
Journal Articles

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Madeleine Etienne, CRA, Elodie Gadolet, CRA, Helene Labussiere, MD, Sandrine Hayette, PhD, Franck E. Nicolini, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1691.
https://doi.org/10.1182/blood.V118.21.1691.1691
Published: 2011
Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet
Journal: Blood
Blood (2010) 116 (21): 3407.
https://doi.org/10.1182/blood.V116.21.3407.3407
Published: 2010
Journal Articles

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Franck E Nicolini, MD, PhD, Stephane Morisset, Stat., Andreas Hochhaus, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Inge Dufva, MD, Michael Mauro, MD, Jorge E. Cortes, MD, Charles Chuah, MBChB, FRCPE, MD, Jane Apperley, MBChB, FRCP, FRCPath, Francois Guilhot, Giuseppe Saglio, MD, PhD, Martin C. Müller, Simona Soverini, Selim Corm, MD, PhD, Isabelle Tigaud, MD, Madeleine Etienne, CRA, Catherine Roche-Lestienne, PhD, Sandrine Hayette, PhD, Senaka Peter, MPH, Wei Zhou, MD, PhD, Mauricette Michallet, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3410.
https://doi.org/10.1182/blood.V116.21.3410.3410
Published: 2010